VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics

Jinsy A. Andrews1 Eleanor and Lou Gehrig ALS Center, Columbia University, New York, NY, USA,

Merit E. Cudkowicz2 Department of Neurology, Massachussetts General Hospital, Boston, MA, USA,

Orla Hardiman3 Biomedical Sciences Institute of Neurosciences, The University of Dublin, Dublin, Ireland,

Lisa Meng4 Cytokinetics, Inc, South San Francisco, CA, USA, and

Amy Bian4 Cytokinetics, Inc, South San Francisco, CA, USA, and

Jacqueline Lee4 Cytokinetics, Inc, South San Francisco, CA, USA, and

Andrew A. Wolff4 Cytokinetics, Inc, South San Francisco, CA, USA, and

Fady I. Malik4 Cytokinetics, Inc, South San Francisco, CA, USA, and

Jeremy M. Shefner5 Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USACorrespondence[email protected]

Related Research Data